Aktienanalyse zu Insmed Inc (INSM)INSMInsmed Inc

Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Insmed Inc (INSM) is currently not a strong buy due to its low RSI of 24.37, indicating oversold conditions, and a significant year-to-date change of -47.27%. While the recent FDA priority review for ARIKAYCE is a positive catalyst, the company's financials show a forward P/E of 97.09 and a negative net income of -13,242,000 USD in Q2 2026, which raises concerns about profitability. The main risk is the high forward P/E ratio, suggesting that the stock may be overvalued given its current financial performance.

8 analysts cover INSM: 7 rate it Buy, 1 Hold and 0 Sell. The average price target is 219.50.